Hemorrhagic disease of newborn

Summary

Hemorrhagic disease of newborn (MONDO:0006784) is a disease. A subtype of blood coagulation disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	hemorrhagic disease of newborn
Mondo ID	MONDO:0006784
EFO	EFO:1000964
MeSH	D006475
ICD-10-CM	P53
NCIT	C111857
SNOMED CT	12546009
UMLS	C0019088
MedGen	42406
GARD	0024471
MedDRA	10019601
Is cancer (heuristic)	no

Also known as: hemorrhagic disease of newborn · vitamin K deficiency bleeding in newborn

Disease family

This is a subtype of blood coagulation disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › hematologic disorder › blood coagulation disease › hemorrhagic disease of newborn

Related subtypes (7): marantic endocarditis, hemolytic-uremic syndrome, coagulation protein disease, thrombophilia, thrombotic microangiopathy, inherited blood coagulation disorder, prekallikrein deficiency

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.